The School of Medicine at Makerere University College of Health Sciences, created in 1924 as a Faculty of Medicine, is the oldest and leading medical school in East Africa. The School of Medicine, at Mulago National Referral and Teaching Hospital Complex, provides training, research, and patient care as its major mandates. Our medical school has produced the country’s most influential leaders in healthcare, research and politics.
We deliver competence-based student-centred curricular in medicine and surgery for medical students pursuing Bachelor of Medicine and Bachelor of Surgery (MBChB), Bachelor of Science in Medical Radiography (BSMR), Bachelor of Speech and Language Therapy (BSLT) and Bachelor of Palliative care; to create a skilled health workforce for Uganda and the rest of the world.
Our programs provide opportunities for community-based education and research to expose our students to the “real life” community experiences in health care delivery, in addition to the clinical training offered at Mulago National Referral and Teaching hospital.
We also offer graduate training programs that include three-year Master of Medicine (MMED) programs in all clinical specialties, Doctor of Philosophy (PhD) programs, and a Medical doctorate (MD) program for clinical subspecialty training. Our graduate programs are highly competitive in the region and graduate trainees constitute up to 50% of the student population at the School of Medicine.
The school has increasingly provided groundbreaking research to improve health since the 1950s in multiple ways. Burkitt lymphoma was first detected in Uganda, initially described as a sarcoma of the jaw and subsequently, in 1962, discovered to be a distinct form of Non-Hodgkin lymphoma [1–3]. This led to the establishment in 1967 of a dedicated cancer research institute, the Uganda Cancer Institute . Similarly, in 1970, research on Kaposi’s sarcoma was conducted in Uganda by Dr. Kyalwazi through early immunological studies, where a striking impairment in the delayed hypersensitivity response to dinitrochlorobenzene was noted in patients with a “malignant” type of tumor . Fast forward to 1985, when “Slim disease” was described by three Makerere University scientists as a new disease associated with HTLV-III infection . Subsequently, the 1999 landmark HIVNET 012 study showed that single-dose Nevirapine at the onset of labor and a single dose to the infant led to a 42 percent reduction in maternal to child HIV transmission, providing the developing world with a cheap and simple option to protect thousands of children born by HIV-infected mothers [7, 8].
My vision is to create a conducive environment that develops life-long learners and transformational leaders in science and innovation to meet our global community’s health needs in the 21st Century.
I am privileged to work with a set of brilliant clinicians and researchers in 13 clinical departments each led by a departmental head to fulfill this vision.
To our students, I encourage you not to be afraid of making excellence a habit. Clinicians value lives and treat them with dignity and excellence. Excellent clinicians with inquisitive minds are always looking for what will make their patients feel better and that drives the commitment to research in the school of Medicine.
As the oldest medical school in the region, we focus on excellence in training, clinical care and research; as evidenced by our affiliated centres of excellence that include the Infectious Diseases Institute, Makerere Joint AIDS Program, Lung Institute, Makerere University Johns Hopkins Collaboration, and the Makerere University-Uganda Virus Research Institute Infection and Immunity program (MUII); among others. We have several international training and research collaborations with academic and research institutions globally.
Do not hesitate to contact us at email@example.com with any feedback and suggestions on how we can serve you better.
Professor Damalie Nakanjako
(MBChB, MMED, PhD)
Dean School of Medicine
College of Health Sciences,